Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 69.4 3.32% 2.23
DCPH closed up 3.32 percent on Friday, January 17, 2020, on 79 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical DCPH trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Stochastic Reached Overbought Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Crossed Above 20 DMA Bullish 6.15%
Multiple of Ten Bullish Other 11.58%
20 DMA Resistance Bearish 11.00%
Pocket Pivot Bullish Swing Setup 11.00%
NR7 Range Contraction 11.00%
Up 3 Days in a Row Strength 11.00%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Medicine Biopharmaceutical Cancer Drugs Immune System Cancer Treatments Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Protein Kinase Inhibitor Glioblastoma Multiforme Mastocytosis Systemic Mastocytosis Treatment For Cancer

Is DCPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 70.0
52 Week Low 19.88
Average Volume 552,695
200-Day Moving Average 35.42
50-Day Moving Average 56.67
20-Day Moving Average 63.46
10-Day Moving Average 62.74
Average True Range 2.91
ADX 32.12
+DI 35.23
-DI 17.27
Chandelier Exit (Long, 3 ATRs ) 61.28
Chandelier Exit (Short, 3 ATRs ) 64.12
Upper Bollinger Band 71.06
Lower Bollinger Band 55.87
Percent B (%b) 0.89
BandWidth 23.93
MACD Line 2.40
MACD Signal Line 2.17
MACD Histogram 0.2266
Fundamentals Value
Market Cap 2.22 Billion
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -4.33
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 73.87
Resistance 3 (R3) 73.53 71.71 73.13
Resistance 2 (R2) 71.71 70.57 71.88 72.88
Resistance 1 (R1) 70.55 69.87 71.13 70.89 72.63
Pivot Point 68.73 68.73 69.02 68.90 68.73
Support 1 (S1) 67.57 67.59 68.15 67.91 66.17
Support 2 (S2) 65.75 66.89 65.92 65.92
Support 3 (S3) 64.59 65.75 65.68
Support 4 (S4) 64.93